share_log

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

摩根士丹利维持对Cytek Biosciences的同等权重,将目标股价下调至7美元
Benzinga ·  2023/11/09 09:02

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $8 to $7.

摩根士丹利分析师Tejas Savant维持Cytek Biosciences(纳斯达克股票代码:CTKB)的权重持平,并将目标股价从8美元下调至7美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发